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Abstract
Background
Psoriasis (PsO) is a chronic inflammatory disease with predominantly cutaneous manifesta-
tions. Approximately one third of patients with PsO develop psoriatic arthritis (PsA), whereas
the remaining proportion of patients has isolated cutaneous psoriasis (PsC). These two phe-
notypes share common immunology, but with different heredity that might in part be
explained by genetic variables.
Methods
Using a candidate gene approach, we studied 53 single nucleotide polymorphisms (SNPs)
in 37 genes that regulate inflammation. In total, we assessed 480 patients with PsO from
DERMBIO, of whom 151 had PsC for 10 years or more (PsC10), 459 patients with PsA from
DANBIO, and 795 healthy controls. Using logistic regression analysis, crude and adjusted
for age and gender, we assessed associations between genetic variants and PsO, PsC10,
and PsA, as well as associations between genetic variants and development of PsA in PsO.
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Results
Eleven polymorphisms in 10 genes were nominally associated with PsO and/or PsC and/or
PsA (P < 0.05). After correction for multiple testing with a false discovery rate of 5%, two
SNPs remained significant: TNF (rs361525) was associated with PsO, PsC10, and PsA;
and IL12B (rs6887695) was associated with PsO.
Conclusion
Among a cohort of Danish patients with moderate-to-severe psoriasis, two SNPs in the
IL12B and TNF genes were associated with susceptibility of psoriasis. None of the SNPs
were specifically associated with isolated cutaneous psoriasis or psoriatic arthritis.
Introduction
Psoriasis (PsO) is a chronic inflammatory disease that affects approximately 2–4% of the west-
ern world’s population [1]. Approximately one third of patients with PsO develop psoriatic
arthritis (PsA) [2], while the remaining patients have isolated cutaneous psoriasis (PsC). PsA
and PsC share common immunology, in which the interleukin (IL)-23/IL-17 axis plays a criti-
cal pathogenic role [3]. Other important cytokines include tumor necrosis factor alpha (TNF-
α), interleukin (IL)-12, IL-22, and interferon gamma (IFN-γ) [4, 5], with NFκB being a crucial
mediator in the pathogenesis [6].
Epidemiological studies suggest stronger heritability for PsA than for PsC (9) which indi-
cates that there could be individual risk loci for these two disease entities. Identification of
such loci could potentially serve as novel drug targets and possibly improve patient outcomes
by facilitating earlier detection of PsA, thereby possibly preventing irreversible joint destruc-
tion [7–9]. Indeed genetic differences related to the human leukocyte antigen (HLA) class I
region of the major histocompatibility complex (MHC) have been well established. Variants of
HLA-B, namely HLA-B27, have been proven to confer risk of PsA [10], while HLA-C06 has
been demonstrated to hold a specific risk for PsC [10–14].
Only a limited number of studies have evaluated genetic loci specifically associated with
PsA, PsC and the differences between PsA and PsC. To date only 15 polymorphisms in twelve
genes outside the MHC region have been reported to render differences in susceptibility
between the two phenotypes, including IL23R (rs2201841, rs12044149) [11, 12, 15], FBXL19
(rs10782001) [16], IL12B (rs2082412) [11, 17], ZNF816A (rs9304742) [17], CCR2 (rs1799864)
[18], CSF2 (rs715285) [19], PTPN22 (rs2476601) [12, 20], IL13 (rs1800925, rs20541, rs848)
[21–23], TNFRSF9 (rs4908742) [12], LCE3A (rs10888503) [12], TNFAIP3 (rs9321623) [12],
and KIR2DS2 [24]. Among these, only associations to PTPN22 (rs2476601) [12, 20], IL23R
(rs2201841, rs12044149) [11, 12, 15], IL12B (rs2082412) [11, 17], and IL13 (rs1800925,
rs20541, rs848) [21–23] have been replicated, while a large scale genome wide association
study (GWAS) failed to reproduce the associations for the polymorphisms in IL13 and IL12B
[12].
In order to potentially add to the number of loci outside of the HLA region that confer risk
specific to PsA and PsC, this study examined functional single nucleotide polymorphisms
(SNPs) in genes involved in regulation of the NFκB pathway (CD14, LY96, MAP3K14,NFKB1,
NFKBIA, SUMO4, TIRAP,TLR1, TLR2, TLR4, TLR5, and TLR9), cytokines regulated by NFκB
(IL1B, IL1RN, IL6, and IL10), TNF-α signaling (TNFA, TNFAIP3, and TNFRSF1A), IFN-γ
SNPs associated with psoriasis and psoriatic arthritis
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signaling (IFNG, IFNGR1, IFNGR2, JAK2, and TBX21), the IL-23/IL-17 axis (IL12B, IL12RB1,
IL17A, and IL23R), and other genes involved in regulation of inflammation (CARD8, IL4R,
IL6R, IL18, NLRP1, NLRP3, PPARG, PTPN22, and TGFB1). These were assessed for association
with PsO, PsC, and PsA and compared to the general population, and furthermore they were
examined for association with development of PsA in PsO.
Materials and methods
Cohort
As described by Loft et al. a Danish cohort comprising 480 patients, registered in the national
database DERMBIO, diagnosed with PsO was established [25]. Among these patients, 147 had
an additional diagnosis of PsA recorded in DERMBIO [25]. Patients registered in DERMBIO
have all received biological therapy in a dermatological setting, thus all patients had moderate-
to-severe involvement of skin. We identified a subgroup of 151 patients with PsC who had
been retrospectively followed for10 years prior to initiation of biological treatment (PsC10)
and who did not have an additional PsA diagnosis in DERMBIO. This group represented a
group of patients with isolated cutaneous psoriasis who were unlikely to develop PsA, as the
majority of patients with PsO, who develop PsA do so within the first 10 years after diagnosis
[26].
Additionally, a PsA cohort was established. This included 459 patients diagnosed with PsA
according to their treating rheumatologist in DANBIO, an independent Danish nationwide
quality registry for patients treated in a rheumatology setting with disease modifying anti rheu-
matic drugs (DMARDs) including biological (b)DMARDs [27]. There was no overlap of
included patients in DERMBIO and DANBIO.
Patients were identified by linking the unique personal identification number of Danish cit-
izens (CPR number) from blood clot samples, sent for Mycobacterium tuberculosis (TB)
screening, with DANBIO and DERMBIO. Screening for TB before the initiation of biological
therapy is a routine element of care in Denmark. Blood clot samples were obtained from: the
Department of Biochemistry, Hospital of Lillebaelt (Vejle, Denmark); the Department of Bio-
chemistry, Hospital of Slagelse (Slagelse, Denmark); the Department of Clinical Biochemistry,
Herlev and Gentofte Hospital (Hellerup, Denmark); the Department of Respiratory Diseases B
and the Department of Clinical Microbiology, Aarhus University Hospital (Aarhus, Den-
mark); and Statens Serum Institut (Copenhagen, Denmark) from September 2009 through
July 2015, as described earlier [25, 28–31]. A previously described group of 795 healthy blood
donors recruited from Viborg, Denmark was used as control group [32].
Ethical considerations
The study was conducted in accordance with the Declaration of Helsinki and was approved by
Regional Ethics Committees of Southern (S-20120113) and Central (M-20100153) Denmark
and the Danish Data Protection Agency of Southern (RSD: 2008-58-035) and Central (RM: J.
2010-41-4719) Denmark. The Ethics Committees gave exemption from obtaining written
informed consent, because information had no health-related impact.
Genotyping
For the patients, DNA was extracted from cryopreserved blood clots by using the Maxwell 16
Blood purification kit (Promega, Madison, Wisconsin, USA), as described by Bank et al. [33].
DNA from the healthy controls was extracted according to the manufacturers’ instructions
SNPs associated with psoriasis and psoriatic arthritis
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from EDTA-stabilized peripheral blood using either a either PureGene (Qiagen, Hilden, Ger-
many) or Wizard Genomic (Promega, Madison, Wisconsin, USA) DNA purification kit [32].
A candidate gene approach was chosen, with focus on genes involved in the NFκB pathway,
TNF-α signaling, the IFN-γ pathway, and the IL-23/IL-17 axis, as described earlier [28–30]. In
addition, other genes involved in regulation of inflammation including the inflammasome
were assessed [34]. In short, relevant genes were identified by searching pathway databases
(http://www.genome.jp/kegg/pathway.html and http://www.wikipathways.org/index.php/
WikiPathways) and SNP candidates were identified by searching PubMed with “polymorphism
ANDGene name AND (reporter gene OR luciferase OR ELISAOR RT-PCR OR flow cytometry OR
EMSA)”. The SNPs were selected based on the reported functionality or associated with autoim-
mune diseases (S1 Table). Additionally, SNPs or genes associated with response to biological
treatment of either inflammatory bowel diseases or rheumatoid arthritis were included [28–30].
The polymorphisms were genotyped with Competitive Allele-Specific Polymerase chain
reaction (KASP™) by LGC Genomics (LGC Genomics, Hoddesdon, United Kingdom) (http://
www.lgcgenomics.com/). Genotype distributions for healthy controls and phenotypes are pre-
sented in S2 Table.
Linking disequilibrium (LD) was calculated using SNP Annotation and Proxy Search
(SNAP) software (http://archive.broadinstitute.org/mpg/snap/) using as reference the Central
Europeans in the 1,000 Genomes [35].
As a quality control, all SNPs were replicated for 94 randomly selected samples, yielding
>99% identical genotypes.
Power analysis
At the 5% significance level, and a minor allele frequencies (MAF) of 0.05, 0.25, and 0.45 there
is> 80% power for detecting a dominant effect with an odds ratio (OR) of 1.7, 1.4, and 1.5,
respectively, for PsO, an OR of 2.0, 1.7, and 1.9, respectively, for PsC10, an OR of 1.7, 1.4, and
1.5, respectively, for PsA, and for PsA in patients diagnosed with PsO an OR of 1.8, 1.5, and
1.6, respectively (Table 1). The Genetic Power Calculator [36] was used for power calculations,
setting ‘prevalence’ of PsO to 2%, of PsC10 to 1.4%, of PsA to 0.6%, and of PsA in PsO to 30%,
D-prime to 1, type 1 error rate to 0.05, and number of cases and control:case ratio was based
on data described in Table 2.
Statistical analysis
Assuming a dominant model, we compared genotype distributions for the following groups:
patients with PsO and PsC10 from DERMBIO compared with healthy controls using logistic
regression analysis; patients with PsA from DANBIO compared with healthy controls; patients
Table 1. Minimum effect size in which we had> 80% power at 5% significance level and a minor allele frequency (MAF) of 0.05, 0.25, and 0.45 for each phenotype.
Phenotype ‘Prevalence’ MAF = 0.05 MAF = 0.25 MAF = 0.45
PsO 2.0% 1.7 1.4 1.5
PsC10 1.4% 2.0 1.7 1.9
PsA 0.6% 1.7 1.4 1.5
PsA in PsO 30% 1.8 1.5 1.6
Abbreviations: MAF, minor allele frequencies; PsO, psoriasis; PsA, psoriatic arthritis; PsC, cutaneous psoriasis; PsC10, patients with PsC followed for 10 years or more.
The Genetic Power Calculator [36] was used for power calculations, setting ‘prevalence’ according to corresponding phenotype, D-prime to 1, type 1 error rate to 0.05
and number of cases and control:case ratio was based on data described in Table 2.
https://doi.org/10.1371/journal.pone.0192010.t001
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with PsA from DANBIO compared to patients with PsC10 from DERMBIO. Odds ratios
unadjusted and adjusted for age and gender are reported (S3 and S4 Tables). Correction for
multiple testing by controlling the false discovery rate (FDR) at 5% was performed [37]. Addi-
tional computation of FDR-adjusted p-values (q-values) based on all P-values presented in S3
and S4 Tables were performed. Q-values describe the estimated proportion of false positives
among associations equal to, or more extreme than, the observed association.
Chi-square test was used to test deviations from Hardy-Weinberg equilibrium among
healthy controls. Statistical analyses were performed using Stata version 14 (StataCorp LP, Col-
lege Station, TX, USA).
Results
Study population
The characteristics of patients and healthy controls are shown in Table 2. The genotype distri-
butions among healthy controls deviated from Hardy-Weinberg equilibrium for TGF-B1
(rs1800469) (P = 0.016), TLR1 (rs4833095) (P = 0.028), TLR2 (rs4696480) (P = 0.018), and
TLR4 (rs1554973) (P = 0.032). After correction for multiple testing, none of the deviations
remained statistically significant.
Polymorphisms associated with the risk of PsO in the general population
The association of SNPs in patients with PsO was compared with healthy controls using a
dominant model for association. Nine SNPs were nominally associated with PsO (P< 0.05)
(S3 Table). Two SNPs [TNF (rs361525) and IL12B (rs6887695)] withstood correction for mul-
tiple testing (Table 3).
Polymorphisms associated with the risk of PsC10 in the general population
Patients were stratified for phenotype and diseased duration, and the genotype distributions of
patients with PsC10 were compared with healthy controls. Five SNPs were nominally associ-
ated with PsC10 (S3 Table), among which one SNP [TNF (rs361525)] withstood correction for
multiple testing (Table 3).
Table 2. Characteristics and demographics of patients with psoriasis, psoriatic arthritis, cutaneous only psoriasis, and healthy controls.
PsO
(n = 480)
PsC10
(n = 151)
#PsA
(n = 459)
Controls
(n = 795)
Gender, n (%):
Male 285 (59) 99 (66) 209 (46) 411 (52)
Female 195 (41) 52 (34) 250 (54) 384 (48)
Age, years:
Mean (SD) 44 (14) 45 (14) 46 (13) 43 (12)
Age at diagnosis, years:
Mean (SD) 24 (14) 21 (13) 41 (13) -
Disease duration, years:
Mean (SD) 20 (13) 25 (12) 5 (7) -
Abbreviations: PsO, psoriasis; PsC, cutaneous psoriasis; PsC10, patients with PsC followed for10 years; PsA, psoriatic arthritis.
#patients registered in DANBIO with PsA.
Diagnosis of PsA
https://doi.org/10.1371/journal.pone.0192010.t002
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Polymorphisms associated with the risk of PsA in the general population
Genotype distributions for patients with PsA from DANBIO were compared with those from
healthy controls using a dominant model for association. Two SNPs were nominally associated
with PsA (S3 Table), with one withstanding correction for multiple testing (Table 3).
Polymorphisms associated with the risk of PsA in patients with PsO
Genotype distributions for patients with PsA from DANBIO were compared with patients
with PsC10. Only TNF (rs361525) (OR: 0.59, 95% CI: 0.38–0.92, P = 0.019, q = 0.32) showed
nominally evidence of association, but this did not withstand correction for multiple testing
(S3 Table).
Discussion
This study evaluated 53 SNPs in 37 genes in 480 Danish patients with moderate-to-severe PsO
and in 459 patients with PsA. The polymorphisms were primarily chosen as functional poly-
morphisms targeting the inflammatory signaling pathways. Eleven polymorphisms in 10 genes
were nominally associated with PsO and/or PsC and/or PsA (P< 0.05), among which two
withstood correction for multiple testing.
The variant alleles in IL12B (rs6887695) [38–45], IL23R (rs11209026) [39–42, 46, 47], and
TNF (rs361525) [48–52] are all well-known polymorphism associated with susceptibility to
PsO. We found that the variant allele of IL23R (rs11209026) was nominally associated with
decreased risk of PsO, but this did not withstand correction for multiple testing.
In the current study, the variant allele of TNF (rs361525) was the only variant consistently
associated with an increased risk of all phenotypes, thus underlining the importance of TNF-α
signaling in the development of psoriasis. Conflicting results for the association of TNF
(rs361525) and development of PsA in PsO have previously been reported. While some studies
have reported a protective role for the variant allele of TNF (rs361525) in development of PsA
in PsO [53, 54], other studies have reported increased or no altered risk for development of
PsA in PsO [55, 56]. In the current study, the variant allele of TNF (rs361525) was associated
with an increased risk of PsA and nominally associated with a decreased risk of developing
PsA in PsO. The strong association between PsO and TNF (rs361525), and the increased risk
Table 3. Risk estimates for carriers of the variant allele compared to homozygous carriers of the wild type allele.
Gene Rs number
MAF
(cases)
MAF
(controls)
Odds ratio
(95% CI) P-value
q-value
Effect of minor allele
PsO compared to healthy controls
IL12B
G/C rs6887695 0.23 0.29 0.68 (0.54–0.85) 0.0010 0.047 Unknown [64] [65]
TNF
G/A rs361525 0.13 0.04 3.57 (2.49–5.11) < 1.0 x 10−6 0.00011 Decreased expression [66]
PsC10 compared to healthy controls
TNF
G/A rs361525 0.14 0.04 3.81 (2.45–5.98) < 1.0 x 10−6 0.00011 Decreased expression [66]
PsA compared to healthy controls
TNF
G/A rs361525 0.09 0.04 2.24 (1.57–3.20) 9.0 x 10−6 0.00064 Decreased expression [66]
Abbreviations: MAF, minor allele frequencies; PsO, psoriasis; PsA, psoriatic arthritis; PsC, cutaneous psoriasis; PsC10, patients with PsC followed for10 years; CI,
confidence interval.
https://doi.org/10.1371/journal.pone.0192010.t003
SNPs associated with psoriasis and psoriatic arthritis
PLOS ONE | https://doi.org/10.1371/journal.pone.0192010 February 1, 2018 6 / 12
of PsC compared to PsA have been suggested to be due to a high LD between TNF (rs361525)
and HLA-CW6 [54].
Another SNP investigated, IL12B (rs3212217), is in close LD with two other polymor-
phisms: IL12B (rs3212227, r2 = 0.95) [38–45, 57] and IL12B (rs2082412, r2 = 0.95) [11, 17],
both associated with reduced risk of PsO. Differences in effect size between PsC and PsA for
IL12B (rs2082412) have been reported [11, 17] although the associations could not be repli-
cated by a large GWAS that attempted to confirm previously reported associations [12]. In the
current study, no statistically significant difference in effect size between PsA and PsC10 for
IL12B (rs3212217) was observed. Thus the current study adds to the evidence that suggest that
there is no difference in PsA and PsC10 susceptibility for the variants in IL12B.
In a previous study, the variant allele of PPARG (rs1801282) was associated with decreased
risk of PsA [58]. Another study demonstrated the same trend, although the findings were not
statistically significant [59]. In the current study, the variant allele of PPARG (rs1801282) was
nominally associated with decreased risk of PsA, with odds ratios similar to those previously
reported, but the association was not statistically significant after correction for multiple test-
ing. In accordance with previous studies [60], we observed no association between PPARG
(rs1801282) and uncomplicated psoriasis, PsO or PsC10. Additional studies investigating asso-
ciation of PPARG (rs1801282) with PsA should be performed in order to clarify the role of
PPARG (rs1801282) in PsA. PPARG (rs1801282) encodes a Pro to Ala amino acid substitution
in PPARG that leads to reduced activity. PPARG (rs1801282) is a variant of notable interest
that has, in addition to PsA, been associated with a lower risk of alcohol-related breast cancer
[61, 62], but an increased risk of alcohol-related colorectal cancer [63] likely because PPARG
inhibits sex hormone synthesis via negative regulation of aromatase [62].
We failed to replicate PTPN22 (rs2476601) as a risk factor of PsA in PsO, probably due to
lack of power, since we observed odds ratios similar to those previous reported [12, 20].
The main limitation in this and other studies evaluating risk of PsA in PsO is the potential
for phenotype misclassification, which inevitably will lead to a decrease in statistical power. In
this study, data on PsA, for the DERMBIO cohort, were retrieved from the DERMBIO data-
base, with patient registration performed by dermatologists. Although dermatologist are expe-
rienced and trained in assessing PsA, we cannot rule out the possibility that some patients with
PsC may have had undiagnosed or undeveloped PsA. This might bias the effect size towards
the null hypothesis of no difference. In order to overcome the possibility of undeveloped PsA
and reduce the risk of undiagnosed PsA, a cohort of patients with PsC who had the disease for
10 years (PsC10) was established, as proposed by Stuart et al [12]. Similarly, there is risk of
potential misclassification in the PsA cohort (e.g. rheumatoid arthritis or osteoarthritis). How-
ever, this risk was lowered by only including patients registered in DANBIO, where diagnoses
are according to the treating rheumatologist.
In conclusion, this study confirms that two SNPs in the IL12B and TNF genes are associated
with susceptibility to psoriasis in Danish patients with moderate-to-severe psoriasis. None of
the investigated SNPs were specifically associated with isolated cutaneous psoriasis or psoriatic
arthritis.
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